Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 7, 2026

Traders Snatch Up Derivatives as Risks Grow: Credit Weekly

View original at finance.yahoo.com
Traders Snatch Up Derivatives as Risks Grow: Credit Weekly DTCC, Barclays (Bloomberg) -- War in Iran. A weakening US jobs market. Artificial intelligence and the potential demise of whole industries…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fund withdrawal limits are generally features and not bugs

    80% confidence
  • Bullish bets in credit default swap indexes have been eroding over the past few weeks amid anxiety over the software sector

    80% confidence
  • Private credit default rates could reach 15%

    80% confidence
  • The concerns in the market are a ton of noise

    80% confidence
  • We don't want to be in a position where we have to be reactive during a market downturn. The company is instead in a position to snatch up bargains if they arise.

    80% confidence
  • With record fundraising following the 2008 financial crisis, direct-lending vehicles have loosened their underwriting standards and are due for a default cycle

    80% confidence
  • Business development companies are sitting on a massive pile of leveraged loans which could be sold to meet redemption requests and push spreads wider

    80% confidence
  • War on its own doesn't tend to directly impact corporate bond spreads or returns, and valuations tend to be driven more by what the Fed is doing amid the conflict

    80% confidence
  • UBS forecast that private credit default rates could reach 15% was absolutely wrong

    80% confidence
  • Doesn't see cause for concern in private credit, but the firm is watching closely to see if there's been too much frothiness

    80% confidence
  • There needs to be a material catch-up between the risks the market is worried about in private capital and geopolitics and the risks being reflected in high grade corporate bond spreads. This is a very good time to be looking at credit hedges.

    80% confidence
  • X and xAI will repay the outstanding debt in full

    80% confidence
  • If the US central bank eventually has to start boosting rates, credit could get hit

    80% confidence
  • Investors can still reposition for risks that appear skewed to the downside. Recent geopolitical events, along with AI, software and private credit, are increasingly interconnected. That's likely to create clearer winners and losers.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com